2016 Press Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
08/10/16Cipher Pharmaceuticals Reports Q2 2016 Results Highlighted by 32% Revenue Growth and $3.1 Million Cash from Operations
MISSISSAUGA, ON, Aug. 10, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended June 30, 2016. Unless otherwise noted, all figures are in U.S. currency. Q2 2015 financial information includes results of U.S. operations starting April 13, 2015, the date of the Innocutis acquisition. "It was a solid second quarter for the Company, highlighted by 32% revenue growth and a... 
Printer Friendly Version
08/09/16Cipher Pharmaceuticals Inc. Announces Changes to its Board of Directors
MISSISSAUGA, ON, Aug. 9, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher") today announced certain changes to its board of directors (the "Board"). As previously disclosed, a special committee of the Board (the "Special Committee") was established to address the issues of the type referred to in an early warning report filed on July 5, 2016 by 1207407 Ontario Limited, a company wholly-owned by Dr. John D. Mull. The Special Committee, after communications wi... 
Printer Friendly Version
08/03/16Cipher Pharmaceuticals Announces Preliminary Q2 2016 Results Highlighted by 30+% Revenue Growth and $3.0+million Cash from Operations
MISSISSAUGA, ON, Aug. 3, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced preliminary estimates of its financial results for the three months ended June 30, 2016. The complete financial statements for the Company's second quarter will be released on August 10, 2016, followed by a conference call with management. These preliminary financial results are subject to completion of the Company's customary quarterly closing and review pr... 
Printer Friendly Version
07/20/16Notice of Cipher Pharmaceuticals Inc. Q2 2016 Conference Call
MISSISSAUGA, ON, July 20, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) today announced it will host a conference call for its Q2 2016 financial results on Wednesday, August 10, 2016. Q2 2016 CONFERENCE CALL WHEN: Wednesday, August 10, 2016 at 8:30AM ET CONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through www.cipherpharma.com or http://bit.ly/29SSbts. An archived replay of the w... 
Printer Friendly Version
07/12/16Cipher Pharmaceuticals announces Ozenoxacin accepted for review by Health Canada
MISSISSAUGA, ON, July 12, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that its New Drug Submission for Ozenoxacin has been accepted for review by Health Canada. Ozenoxacin is a topical treatment proposed for use in adult and paediatric patients with impetigo, a highly contagious bacterial skin infection. Cipher acquired the Canadian commercialization rights to Ozenoxacin from Ferrer International SA ("Ferrer"), a privately-he... 
Printer Friendly Version
07/06/16Special Committee of Cipher Pharmaceuticals Responds to Early Warning Report Filed by 1207407 Ontario Limited
MISSISSAUGA, ON, July 6, 2016 /PRNewswire/ - A special committee (the "Special Committee") of the board of directors (the "Board") of Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher") responded today to an Early Warning Report (the "EWR") filed on July 5, 2016 by 1207407 Ontario Limited ("1207407"), a company wholly owned by Dr. John D. Mull.  The Special Committee, comprised of directors Stephen Wiseman, Thomas Wellner, William Claypool and Stefan Aigner, was established to address ... 
Printer Friendly Version
06/20/16Cipher Pharmaceuticals Out-Licenses Rights to ASF-1096 for Anorectal Disorders
MISSISSAUGA, ON, June 20, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Edesa Biotech Inc. ("Edesa") has licensed the rights to ASF-1096 (R-salbutamol) for use in anorectal disorders. ASF-1096 is a phase II product candidate that Cipher is investigating as a treatment for selected inflammatory skin disorders. Cipher acquired the global rights to the product in February 2015. Under this agreement, Cipher retains all rights ... 
Printer Friendly Version
05/31/16Cipher Pharmaceuticals to Present at Two Upcoming U.S. Investor Conferences
MISSISSAUGA, ON, May 31, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Shawn Patrick O'Brien, President and Chief Executive Officer, will present at two upcoming investor conferences. Jefferies 2016 Healthcare Conference in New York on June 10 at 8:30 a.m. ET. JMP Securities 2016 Life Sciences Conference in New York on June 22 at 2:00 p.m. ET. Both conference presentations will be webcast live. To access the... 
Printer Friendly Version
05/06/16Cipher Pharmaceuticals Reports Voting Results from Annual and Special Meeting of Shareholders
MISSISSAUGA, ON, May 6, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual and Special Meeting of Shareholders held on May 5, 2016 in Toronto, Ontario. A total of 18,005,470 common shares representing 68.82% of the Company's issued and outstanding common shares were voted in connection with the meeting. Shareholders voted in favour of all items ... 
Printer Friendly Version
05/05/16Cipher Pharmaceuticals Reports Q1 2016 Financial Results
-     Revenue increased 23% -     Delivered on multiple commercial and regulatory milestones -     Positive cash from operating activities of $1.4 million while investing in future growth MISSISSAUGA, ON, May 5, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three months ended March 31, 2016. Unless otherwise noted, all figures are in U.S. currency. "In the first quarter,... 
Printer Friendly Version
<< First | Previous | Next | Last >>